NEWS SUMMARY: FERROVIAL, GRIFOLS, IBERDROLA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. US inflation continues to follow the script European stock markets ended with drops, although the US inflation data helped distance them from daily lows. In the STOXX 600 the best-performing sectors were Energy and Consumer Goo...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FERROVIAL, GRIFOLS, IBERDROLA. EUROPA: ASML, DEUTSCHE TELEKOM, PROSUS, SIEMENS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. La inflación estadounidense sigue el camino esperado Las bolsas europeas terminaron con caídas, aunque el dato de i...
A director at Iberdrola S.A. bought 10,000 shares at 13.740EUR and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
NEWS SUMMARY: IBERDROLA, ROVI, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. IBEX leading the way once again It was a negative session on both sides of the Atlantic, except for the IBEX, in another day with all eyes on results. In the Stoxx 600, most of the sectors (15/20) ended with losses, led by Basic Ma...
>Opinion Neutre et OC à 15.3 € maintenus - Les résultats du 9M 24 sont ressortis un peu au-dessus de nos attentes et de celles du consensus. Comme attendu, la stratégie de résilience du groupe lui permet de bénéficier, sur les trois premiers trimestres, de la progression des activités régulées grâce à la croissance de la base d’actifs et aux révisions tarifaires. Cela a permis de largement compenser une activité de génération bénéficiant certes d’un bon niveau d’hydro...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, ROVI, VISCOFAN. EUROPA: DANONE, DEUTSCHE TELEKOM, KERING, SIEMENS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El Ibex volvió a liderar Jornada negativa a ambos lados del Atlántico salvo para el Ibex en una nueva sesión descarg...
>Neutral recommendation and € 15.3 target price maintained - Earnings for the first nine months of 2024 came in slightly higher than we and the consensus had forecast. As expected, the group’s strategy to become more resilient allowed it to benefit over the first three quarters from an increase in regulated activities thanks to growth in the asset base and revised tariffs. This handily offset the generation business, which although it benefited from satisfactory hydro...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
>Recurring 9M 2024 results slightly above our expectations and the consensus - The company just disclosed its figures for 9M 2024. Based on recurring (i.e. excluding the € 1.7bn capital gain from Mexico assets disposal), 9M 2024 performance is slightly above our expectations and the market estimates. Recurring EBITDA reached € 11,551m (+11.0%) vs € 10,783m in 9M 2023, recurring EBIT € 7,354m vs € 6,812m in 9M 2023 and recurring net profit € 4,305m (+22.0%) vs € 3,636m...
>Recurring 9M 2024 results slightly above our expectations and the consensus - The company just disclosed its figures for 9M 2024. Based on recurring (i.e. excluding the € 1.7bn capital gain from Mexico assets disposal), 9M 2024 performance is slightly above our expectations and the market estimates. Recurring EBITDA reached € 11,551m (+11.0%) vs € 10,783m in 9M 2023, recurring EBIT € 7,354m vs € 6,812m in 9M 2023 and recurring net profit € 4,305m (+22.0%) vs € 3,636m...
3Q'24 vs. 3Q'23 Results EBITDA: € 3.654 Bn (+13.4% vs. +8.2% BS(e) and +19.4% consensus); Net Profit: € 1.336 Bn (+19.7% vs. +10.3% BS(e) and +1.5% consensus); 9M'24 vs. 9M'23 Results EBITDA: € 11.551 Bn (+7.1% vs. +5.6% BS(e) and +8.9% consensus); Net Profit: € 4.305 Bn (+18.4% vs. +15.5% BS(e) and +12.8% consensus);
3Q'24 vs. 3Q'23 Results Sales: € 284.9 M (+1.7% vs. +3.6% BS(e) and +2.0% consensus); EBITDA: € 36.2 M (+24.0% vs. +23.2% BS(e) and +19.2% consensus); EBIT: € 18.0 M (+30.4% vs. +44.8% BS(e) and +31.9% consensus); Net Profit: € 3.8 M (-5.0% vs. +49.6% BS(e) and +22.5% consensus); 9M'24 vs. 9M'23 Results Sales: € 856.3 M (+0.6% vs. +1.3% BS(e) and +0.7% consensus); EBITDA: € 107.5 M (+7.1% vs. +6.9% BS(e) and +5.7% consensus); EBIT: € 58.6 M (+8.7% vs. +12.4% BS(e) and +9.1% consensus); Net Profi...
Rdos. 3T'24 vs 3T'23: EBITDA: 3.654 M euros (+13,4% vs +8,2% BS(e) y +19,4% consenso); BDI: 1.336 M euros (+19,7% vs +10,3% BS(e) y +1,5% consenso); Rdos. 9meses'24 vs 9meses'23: EBITDA: 11.551 M euros (+7,1% vs +5,6% BS(e) y +8,9% consenso); BDI: 4.305 M euros (+18,4% vs +15,5% BS(e) y +12,8% consenso).
Rdos. 3T'24 vs 3T'23: Ventas: 284,9 M euros (+1,7% vs +3,6% BS(e) y +2,0% consenso); EBITDA: 36,2 M euros (+24,0% vs +23,2% BS(e) y +19,2% consenso); EBIT: 18,0 M euros (+30,4% vs +44,8% BS(e) y +31,9% consenso); BDI: 3,8 M euros (-5,0% vs +49,6% BS(e) y +22,5% consenso). Rdos. 9meses'24 vs 9meses'23: Ventas: 856,3 M euros (+0,6% vs +1,3% BS(e) y +0,7% consenso); EBITDA: 107,5 M euros (+7,1% vs +6,9% BS(e) y +5,7% consenso); EBIT: 58,6 M euros (+8,7% vs +12,4% BS(e) y +9,1% consenso); BDI: 20,1 ...
NEWS SUMMARY: ENERGY SECTOR, GLOBAL DOMINION, IBERDROLA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. Debt cools the markets European stock markets ended flat in a session marked by the doubts surrounding the sustainability of sovereign debt. In the STOXX 600, Technology led the gains, with Utilities and Insurance p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.